Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $24.00.
Several research analysts have weighed in on IOVA shares. StockNews.com upgraded shares of Iovance Biotherapeutics to a “sell” rating in a research report on Monday, August 12th. Piper Sandler cut Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $19.00 to $10.00 in a report on Monday, July 29th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of Iovance Biotherapeutics in a report on Monday, August 12th. Finally, JMP Securities lowered their target price on Iovance Biotherapeutics from $25.00 to $23.00 and set a “market outperform” rating on the stock in a report on Thursday, June 20th.
Read Our Latest Analysis on IOVA
Institutional Trading of Iovance Biotherapeutics
Iovance Biotherapeutics Price Performance
IOVA opened at $10.46 on Friday. Iovance Biotherapeutics has a 12 month low of $3.21 and a 12 month high of $18.33. The stock has a market capitalization of $2.93 billion, a P/E ratio of -5.81 and a beta of 0.63. The business has a 50 day simple moving average of $9.36 and a 200-day simple moving average of $11.16.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.01. Iovance Biotherapeutics had a negative return on equity of 65.04% and a negative net margin of 1,343.27%. The company had revenue of $31.11 million during the quarter, compared to the consensus estimate of $24.59 million. During the same quarter last year, the company earned ($0.47) earnings per share. Iovance Biotherapeutics’s quarterly revenue was up 12969.7% compared to the same quarter last year. Research analysts anticipate that Iovance Biotherapeutics will post -1.26 EPS for the current year.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
Recommended Stories
- Five stocks we like better than Iovance Biotherapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Emerging Markets: What They Are and Why They Matter
- How to Calculate Return on Investment (ROI)
- Recession or Not, These 3 Stocks Are Winners
- What does consumer price index measure?
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.